JP Morgan Chase
AQST icon

JP Morgan Chase’s Aquestive Therapeutics AQST Stock Holding History

JP Morgan Chase’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-350,000
Closed -$1.74M – 7378
2024
Q3 		$1.74M Buy
+350,000
New +$1.36M ﹤0.01% 4105

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

JP Morgan Chase's AQST Position: Q2 2026 in Review

JP Morgan Chase increased its Aquestive Therapeutics (AQST) stake by 93% in Q2 2026, buying an estimated $253K and bringing the position to 124,505 shares worth $518K. The position accounts for ﹤0.01% of the portfolio, ranked #5083.

JP Morgan Chase first reported a position in AQST in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.65M in Q3 2025. 185 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • JP Morgan Chase held 124,505 shares of Aquestive Therapeutics worth $518K as of Q2 2026.
  • JP Morgan Chase bought 60,067 Aquestive Therapeutics shares in Q2 2026, an estimated $253K.
  • Aquestive Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5083 holding.
  • JP Morgan Chase first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 32 quarters since.
  • JP Morgan Chase's Aquestive Therapeutics position peaked at $2.65M in Q3 2025.
  • 185 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.